Neoadjuvant Immunotherapy Achieves 100% No-Recurrence in MSI-H Colorectal Cancer Trial
A small NEOPRISM-CRC trial at University College London treated stage II/III colorectal cancers with MSI-H/MMR-deficient tumors using pembrolizumab before surgery. After nearly three years of follow-up, no patient experienced cancer recurrence, suggesting neoadjuvant immunotherapy could spare or reduce chemotherapy for this 10–15% subset of bowel cancers, though larger studies are needed to confirm efficacy and applicability.